KALA BIO to Showcase Innovative Eye Therapies
ARLINGTON, Mass. -- KALA BIO, Inc. (NASDAQ: KALA), a pioneering biopharmaceutical company focused on developing therapies for rare and severe ocular conditions, is thrilled to announce an upcoming presentation by Dr. Kim Brazzell, our Head of R&D and Chief Medical Officer. This will take place at the prestigious Piper Sandler 36th Annual Healthcare Conference.
Details of the Presentation
Mark your calendars for this significant event happening on December 4 at 11:30 a.m. ET. Dr. Brazzell will share insights about our innovative advancements in eye health and therapies aimed at enhancing patient outcomes. Following the presentation, our management team will also be available for one-on-one meetings, allowing for in-depth discussions with interested parties.
Accessing the Presentation
For individuals unable to attend in person, we invite you to access the presentation via our website. You can find the live webcast and the subsequent recorded version in the “Presentations” section of the KALA BIO website, ensuring broad accessibility to our research and findings.
About KALA BIO, Inc.
KALA BIO is committed to the research and development of new therapies for severe eye diseases using cutting-edge technology. Our biologics-based investigational therapies are built around our proprietary mesenchymal stem cell secretome (MSC-S) platform. The leading candidate, KPI-012, showcases a unique mixture of human-derived biofactors—like growth factors, protease inhibitors, and neurotrophic factors—which play a crucial role in the healing of corneal defects.
Significance of KPI-012
KPI-012 is currently focused on treating persistent corneal epithelial defects (PCED), a rare condition that can severely impact vision. This product has been granted Orphan Drug and Fast Track designations from the U.S. FDA, demonstrating its potential in the market.
Future Directions for KALA
KALA is not stopping there; we are exploring the development of KPI-012 for treating Limbal Stem Cell Deficiency and other corneal diseases affecting vision. Additionally, preclinical studies are underway to assess the use of our MSC-S platform for retinal degenerative diseases such as Retinitis Pigmentosa and Stargardt Disease—demonstrating our commitment to advancing eye health therapeutics.
Investor Contacts
For further inquiries, investors are encouraged to reach out to Taylor Steiner at taylor.steiner@precisionaq.com or call 212-362-1200 for more information on our developments and upcoming projects.
Frequently Asked Questions
What is KALA BIO, Inc.?
KALA BIO, Inc. is a biopharmaceutical company specializing in innovative therapies for rare and severe diseases of the eye.
What will Dr. Kim Brazzell present at the conference?
Dr. Brazzell will present on KALA's innovative eye health advancements and the potential impacts on patient outcomes.
How can I access the presentation?
The presentation can be accessed through the “Presentations” section of the KALA website, both live and as an archived recording.
What is KPI-012?
KPI-012 is KALA's leading product candidate that aims to correct impaired corneal healing associated with severe ocular diseases.
Who can I contact for investor information?
Investors can contact Taylor Steiner via email at taylor.steiner@precisionaq.com or at 212-362-1200.
